BioVie
BIVI
BioVie (BIVI) news
Recent news
Biovie - Topline results for address-LC expected before end of September 2026
BioVie Inc. (NASDAQ: BIVI) has announced that topline results from its Phase 2 ADDRESS-LC trial evaluating bezisterim for the treatment of neurological symptoms associated with Long COVID are expected before the end of September 2026. The trial, which enrolled approximately 200 patients, is…
AInvest Wire · 5h agoBiovie announces completion of treatment phase of address-LC trial of bezisterim for the treatment of neurological symptoms associated with long COVID
AInvest Wire · 5h agoBiovie - files to offer up to $300 mln in securities - SEC filing
AInvest Wire · Jun 18, 2026ImportantBioVie plunges 64% as its data for Alzheimer’s treatment endpoint misses statistical significance
AInvest Wire · Nov 29, 2023ImportantBioVie surges 31% premarket; Co to present blinded data on NE3107 in treatment of mild to moderate Alzheimers disease
AInvest Wire · Oct 25, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.